- Titel
- SARS-CoV-2 sero-immunity and quality of life in children and adolescents in relation to infections and vaccinations
- Untertitel
- the IMMUNEBRIDGE KIDS cross-sectional study, 2022
- Zitierfähige Url:
- https://nbn-resolving.org/urn:nbn:de:bsz:14-qucosa2-978497
- Quellenangabe
- Infektion
Erscheinungsjahr: 2023
Jahrgang: 51
Seiten: 1531-1539
E-ISSN: 1439-0973 - Erstveröffentlichung
- 2023
- Abstract (EN)
- Purpose: The study evaluates the effects on sero-immunity, health status and quality of life of children and adolescents after the upsurge of the Omicron variant in Germany. Methods: This multicenter cross-sectional study (IMMUNEBRIDGE Kids) was conducted within the German Network University Medicine (NUM) from July to October 2022. SARS-CoV-2- antibodies were measured and data on SARS-CoV-2 infections, vaccinations, health and socioeconomic factors as well as caregiver-reported evaluation on their children’s health and psychological status were assessed. Results: 497 children aged 2–17 years were included. Three groups were analyzed: 183 pre-schoolchildren aged 2–4 years, 176 schoolchildren aged 5–11 years and 138 adolescents aged 12–18 years. Positive antibodies against the S- or N-antigen of SARS-CoV-2 were detected in 86.5% of all participants (70.0% [128/183] of pre-schoolchildren, 94.3% of schoolchildren [166/176] and 98.6% of adolescents [136/138]). Among all children, 40.4% (201/497) were vaccinated against COVID-19 (pre-schoolchildren 4.4% [8/183], schoolchildren 44.3% [78/176] and adolescents 83.3% [115/138]). SARS-CoV-2 seroprevalence was lowest in pre-school. Health status and quality of life reported by the parents were very positive at the time of the survey (Summer 2022). Conclusion: Age-related differences on SARS-CoV-2 sero-immunity could mainly be explained by differences in vaccination rates based on the official German vaccination recommendations as well as differences in SARS-CoV-2 infection rates in the different age groups. Health status and quality of life of almost all children were very good independent of SARS-CoV-2 infection and/or vaccination. Trial registration: German Registry for Clinical Trials Identifier Würzburg: DRKS00025546 (registration: 11.09.2021), Bochum: DRKS00022434 (registration:07.08.2020), Dresden: DRKS 00022455 (registration: 23.07.2020).
- Andere Ausgabe
- Link zum Artikel, der zuerst in der Zeitschrift „Infection” im Verlag Springer erschienen ist.
DOI: 10.1007/s15010-023-02052-5 - Verweis
- Ergänzendes Material ist unter folgendem Link zu finden.
Link: https://link.springer.com/article/10.1007/s15010-023-02052-5#Sec13 - Freie Schlagwörter (EN)
- SARS-CoV-2, Omicron, Seroprevalence, Children and adolescents, Quality of life
- Klassifikation (DDC)
- 610
- Verlag
- Springer, Belin
- Förder- / Projektangaben
- Bundesministerium für Bildung und Forschung (BMBF)
Netzwerk Universitätsmedizin (NUM)
Bridging to large national adaptive population-based panels to generate data on SARS-CoV-2 population immunity correlates in 2022 in Germany
(IMMUNEBRIDGE)
ID: 01KX2121 - Version / Begutachtungsstatus
- publizierte Version / Verlagsversion
- URN Qucosa
- urn:nbn:de:bsz:14-qucosa2-978497
- Veröffentlichungsdatum Qucosa
- 29.04.2026
- Dokumenttyp
- Artikel
- Sprache des Dokumentes
- Englisch
- Lizenz / Rechtehinweis
CC BY 4.0